Aandeel Galapagos AEX:GLPG.NL, BE0003818359

quote:

pardon schreef op 9 december 2014 19:01:

Zijn er maar 6525 is niet de moeite maar wel weer een mooie streek van Onno.

quote:

harrysnel schreef op 9 december 2014 13:17:

Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis
December 09, 2014

FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS
INDIANAPOLIS, Dec. 9, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment. The study included patients with moderately-to-severely active rheumatoid arthritis (RA) who previously failed one or more tumor necrosis factor (TNF) inhibitors and who were taking stable doses of conventional disease-modifying anti-rheumatic drug (cDMARD) therapy. The companies will share results of several ongoing Phase 3 studies in various disclosures in 2015.

"People with rheumatoid arthritis who have had an inadequate response to TNF inhibitors are generally considered to be the least responsive to subsequent treatments," said David Ricks, Lilly senior vice president, and president, Lilly Bio-Medicines. "These results give us further confidence in the potential for baricitinib to be a meaningful treatment option for those suffering from this debilitating condition."

"We are very pleased by these results," said Rich Levy, M.D., chief drug development and medical officer, Incyte Corporation. "Over the next 12 months we look forward to seeing the data from additional Phase 3 studies of baricitinib in rheumatoid arthritis, including patients who have had an inadequate response to conventional DMARDs and in those with earlier stage disease."

The RA-BEACON study enrolled 527 patients who had previously failed at least one anti-TNF therapy, and included a high percentage who had also received prior treatment with one or several non-anti-TNF biologic agents. Patients received either 1 of 2 doses of once daily baricitinib or placebo in addition to their background conventional disease-modifying anti-rheumatic drug therapy (cDMARDs).

The incidence of serious adverse events with baricitinib treatment, including serious infections, was similar to placebo. There were no opportunistic infections or gastrointestinal perforations in the study. A higher incidence of treatment-emergent adverse events was observed with baricitinib compared to placebo. The most common adverse events observed with baricitinib were headache, upper respiratory tract infection and nasopharyngitis. Discontinuation rates due to adverse events were similar between treatment groups. A large majority of patients completing this 6-month trial opted to participate in a long-term extension study.

Detailed data from the RA-BEACON study will be presented at scientific meetings in 2015. Lilly and Incyte are evaluating the safety and efficacy of baricitinib in an extensive Phase 3 program with a total enrollment of over 3,000 people with rheumatoid arthritis.

About Baricitinib
Baricitinib is a once daily, oral, selective JAK1 and JAK2 inhibitor. There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases, suggesting that JAK inhibitors may be useful for the treatment of a broad range of inflammatory conditions. Baricitinib demonstrates approximately 100-fold greater potency of inhibition against JAK1 and JAK2 than JAK 3 in kinase assays.

In December 2009, Lilly and Incyte announced an exclusive worldwide license and collaboration agreement for the development and commercialization of baricitinib and certain follow-on compounds for patients with inflammatory and autoimmune diseases. Baricitinib is currently in Phase 3 clinical development for rheumatoid arthritis and Phase 2 development for psoriasis and diabetic nephropathy.

investor.incyte.com/mobile.view?c=697...

quote:

risky N schreef op 9 december 2014 19:30:

[...]

Aandeel Incyte heeft een plus van 1,5%. Maar je kan er niet uit opmaken in welke mate barictinib effectief is. Zelfs een ARC20-score wordt niet genoemd (en daar moeten we nog even op wachten). De bijwerkingen lijken mee te vallen. Toch hebben patienten last van hoofdpijn, irritatie aan de luchtwegen en last van verkoudheid. En wat wordt er onder een grote meerderheid verstaan, die verder gaat met het vervolgonderzoek? 60%, 70%? Ik vind het persbericht niet heel erg overtuigend.

The primary endpoint of the study was to achieve improved ACR20 response compared to placebo after 12 weeks of treatment. ACR20 response refers to more than 20 percent improvement measured under the American College of Rheumatology criteria.

quote:

itsnotagamble schreef op 10 december 2014 10:49:

Waarom klappen we in elkaar?

quote:

Mr Greenspan schreef op 18 november 2014 18:02:

[...]

Tot 31 december een sprinter naar 15 als tussenstation en dan gaat hij verder als intercity of zo?

Dit jaar nog wel een paar persberichten lijkt me (in ieder geval mbt de alliantie met Johnson & Johnson).

quote:

MtBaker schreef op 11 december 2014 08:58:

Dat is technisch, als de stijging van aandeel van van Herk in galapagos meer bekend wordt kan dat meer mensen aantrekken en mogelijk daling beperken
dan wel stijging laten doorzetten.
Meestal veel persberichten laat in seizoen. dus ik denk wel uit de directe dalende trend maar of het zo doorgaat ljikt me fundamenteel logisch maar technisch niet.

quote:

bioscience schreef op 10 december 2014 11:30:

[...]

Onze Harry ?